George D. Yancopoulos
2017
In 2017, George D. Yancopoulos earned a total compensation of $25.3M as President and Chief Scientific Officer at Regeneron Pharmaceuticals, a 9% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $2,097,984 |
|---|---|
| Option Awards | $21,967,210 |
| Salary | $1,092,700 |
| Other | $141,345 |
| Total | $25,299,239 |
Yancopoulos received $22M in option awards, accounting for 87% of the total pay in 2017.
Yancopoulos also received $2.1M in non-equity incentive plan, $1.1M in salary and $141.3K in other compensation.
Rankings
In 2017, George D. Yancopoulos' compensation ranked 79th out of 14,666 executives tracked by ExecPay. In other words, Yancopoulos earned more than 99.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 79 out of 14,666 | 100th |
Division Manufacturing | 16 out of 5,770 | 100th |
Major group Chemicals And Allied Products | 6 out of 2,074 | 100th |
Industry group Drugs | 5 out of 1,730 | 100th |
Industry Pharmaceutical Preparations | 5 out of 1,329 | 100th |
Source: SEC filing on April 26, 2019.
Yancopoulos' colleagues
We found three more compensation records of executives who worked with George D. Yancopoulos at Regeneron Pharmaceuticals in 2017.
News
Regeneron Pharmaceuticals Executive Vice President and General Manager, Industrial Operations and Product Supply Daniel Van Plew's 2021 pay rises 1% to $8.8M
April 21, 2022
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2020 pay jumps 531% to $135M
April 23, 2021
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2019 pay slips 19% to $21M
April 24, 2020
Regeneron Pharmaceuticals CEO Leonard Schleifer's 2018 pay stays at $27M
April 26, 2019